LAVAL, QC, June 22, 2018 /CNW Telbec/ - Prometic
Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic")
announced today that it will hold a conference call on Wednesday June 27, 2018 to report on its progress
in implementing the updated corporate plan presented during its AGM
on Wednesday May
9th.
Prometic will host a conference call at 12:00pm (ET) on Wednesday June 27, 2018. The
telephone numbers to access the conference call are 1-888-231-8191
and 647-427-7450. An audio replay of the call will be available as
of Wednesday June 27, 2018 at
2:00pm (ET). The numbers to access
the audio replay are 416-849-0833 and 1-855-859-2056 using the
following password (2868257).
A live audio webcast of the conference call will be available
via:
https://event.on24.com/wcc/r/1784311/8AE544873F46749B3B0FCEB9BFBF4B5E
About Prometic
Prometic (www.prometic.com) is a biopharmaceutical corporation
with two drug discovery platforms focusing on unmet medical needs.
The first platform (small molecule therapeutics) stems from the
discovery of two receptors which we believe are at the core of how
the body heals: namely, promoting tissue regeneration and scar
resolution as opposed to fibrosis. One of the lead drug candidates
emerging from this platform, PBI-4050, is expected to enter pivotal
phase 3 clinical trials for the treatment of Idiopathic Pulmonary
Fibrosis (IPF). The second drug discovery and development platform
(plasma-derived therapeutics) leverages Prometic's experience in
bioseparation technologies used to isolate and purify
biopharmaceuticals from human plasma. The Corporation's primary
goal with respect to this second platform is to address unmet
medical needs with therapeutic proteins not currently commercially
available, such as Ryplazimâ„¢ (plasminogen). We are also leveraging
this platform's higher recovery yield potential to advance
established plasma-derived therapeutics such as Intravenous
Immunoglobulin (IVIG). Furthermore, the Corporation is continuing
to secure its plasma supply through the execution of third party
contracts and expansion of its own collection activities for its
plasma processing needs. The Corporation also provides access to
its proprietary bioseparation technologies to enable pharmaceutical
companies in their production of non-competing biopharmaceuticals.
Recognized as a bioseparations expert, the Corporation derives
revenue from this activity through sales of affinity chromatography
media which contributes to offset the costs of its own R&D
investments.
We are headquartered in Laval, Quebec
(Canada) and have R&D facilities in Canada, the United
Kingdom ("UK") and the United
States ("USA"), manufacturing facilities in Canada and the Isle
of Man and corporate and business development activities in
Canada, the USA, and Europe.
Forward Looking Statements
This press release contains
forward-looking statements about Prometic's objectives, strategies
and businesses that involve risks and uncertainties. These
statements are "forward-looking" because they are based on our
current expectations about the markets we operate in and on various
estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our
estimates or assumptions turn out to be inaccurate. Such risks and
assumptions include, but are not limited to, Prometic's ability to
develop, manufacture, and successfully commercialize value-added
pharmaceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of
clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes
in economic conditions. You will find a more detailed assessment of
the risks that could cause actual events or results to materially
differ from our current expectations in Prometic's Annual
Information Form for the year ended December
31, 2017, under the heading "Risk and Uncertainties related
to Prometic's business". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation
to update any forward-looking statement even if new information
becomes available, as a result of future events or for any other
reason, unless required by applicable securities laws and
regulations. All amounts are in Canadian dollars unless indicated
otherwise
View original
content:http://www.prnewswire.com/news-releases/prometic-conference-call-to-present-progress-report-on-agm-corporate-action-plan-300670856.html
SOURCE ProMetic Life Sciences Inc.